Arkolith/Insider Trading/AGIO/Form 4

Jones Cecilia

Chief Financial OfficerAGIOS PHARMACEUTICALS, INC. (AGIO) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$146K
Net Open-Market Flow
-$146K
Transactions
14
8 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Option exercise(M)4K—$047K
Mar 2, 2026Sell(S)2K$28.96$49K43K
Mar 2, 2026Sell(S)1K$28.96$34K46K
Mar 2, 2026Option exercise(M)6K—$044K
Mar 2, 2026Sell(S)594$28.96$17K39K
Mar 2, 2026Option exercise(M)2K—$039K
Mar 2, 2026Sell(S)2K$28.96$46K49K
Mar 2, 2026Option exercise(M)5K—$051K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Option exercise(M)5K—$011K
Mar 2, 2026Option exercise(M)2K—$00
Mar 2, 2026Option exercise(M)6K—$06K
Mar 2, 2026Option exercise(M)4K—$08K
Mar 1, 2026Grant(A)14K—$014K
Mar 1, 2026Grant(A)52K—$052K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001439222-26-000038) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML